Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash from Operations: 2016-2025

Historic Cash from Operations for Summit Therapeutics (SMMT) over the last 8 years, with Sep 2025 value amounting to -$93.1 million.

  • Summit Therapeutics' Cash from Operations fell 207.23% to -$93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$269.7 million, marking a year-over-year decrease of 138.87%. This contributed to the annual value of -$142.1 million for FY2024, which is 85.13% down from last year.
  • Summit Therapeutics' Cash from Operations amounted to -$93.1 million in Q3 2025, which was down 39.46% from -$66.7 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Cash from Operations ranged from a high of $5.2 million in Q4 2022 and a low of -$93.1 million during Q3 2025.
  • Over the past 3 years, Summit Therapeutics' median Cash from Operations value was -$30.3 million (recorded in 2024), while the average stood at -$40.0 million.
  • As far as peak fluctuations go, Summit Therapeutics' Cash from Operations spiked by 156.55% in 2022, and later plummeted by 474.86% in 2023.
  • Over the past 5 years, Summit Therapeutics' Cash from Operations (Quarterly) stood at -$9.2 million in 2021, then soared by 156.55% to $5.2 million in 2022, then plummeted by 474.86% to -$19.5 million in 2023, then crashed by 150.13% to -$48.7 million in 2024, then crashed by 207.23% to -$93.1 million in 2025.
  • Its last three reported values are -$93.1 million in Q3 2025, -$66.7 million for Q2 2025, and -$61.2 million during Q1 2025.